Interações de Elexacaftor + tezacaftor + ivacaftor

Therefore, concomitant use with strong CYP3A inducers is not recommended [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Therefore, concomitant use with strong CYP3A inducers is not recommended [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Therefore, concomitant use with strong CYP3A inducers is not recommended [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Therefore, concomitant use with strong CYP3A inducers is not recommended [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Therefore, concomitant use with strong CYP3A inducers is not recommended [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Therefore, concomitant use with strong CYP3A inducers is not recommended [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Therefore, concomitant use with strong CYP3A inducers is not recommended [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Therefore, concomitant use with strong CYP3A inducers is not recommended [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Therefore, concomitant use with strong CYP3A inducers is not recommended [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Therefore, concomitant use with strong CYP3A inducers is not recommended [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Therefore, concomitant use with strong CYP3A inducers is not recommended [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Therefore, concomitant use with strong CYP3A inducers is not recommended [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Therefore, concomitant use with strong CYP3A inducers is not recommended [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Therefore, concomitant use with strong CYP3A inducers is not recommended [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Therefore, concomitant use with strong CYP3A inducers is not recommended [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Therefore, concomitant use with strong CYP3A inducers is not recommended [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Therefore, concomitant use with strong CYP3A inducers is not recommended [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Lumacaftor/Ivacaftor Not recommended 2 weeks before, during, and 2 weeks after TOLSURA treatment. (bula de Itraconazol, Interações medicamentosas)

Therefore, concomitant use with strong CYP3A inducers is not recommended [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Therefore, concomitant use with strong CYP3A inducers is not recommended [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Therefore, concomitant use with strong CYP3A inducers is not recommended [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Therefore, concomitant use with strong CYP3A inducers is not recommended [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Therefore, concomitant use with strong CYP3A inducers is not recommended [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Therefore, concomitant use with strong CYP3A inducers is not recommended [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Therefore, concomitant use with strong CYP3A inducers is not recommended [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

…delayed offset of the recently discontinued CYP3A inducer [see Drug Interactions (7.3) ] : • Anticancer drugs: apalutamide, enzalutamide • Anticonvulsant: carbamazepine, phenobarbital, primidone, phenytoin • Antimycobacterials: rifampin, rifapentine • Cystic fibrosis transmembrane conductance regulator potentiators: lumacaftor/ivacaftor • Herbal products: St. (bula de Nirmatrelvir + ritonavir, Contraindicações)

Therefore, concomitant use with strong CYP3A inducers is not recommended [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Therefore, concomitant use with strong CYP3A inducers is not recommended [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Therefore, concomitant use with strong CYP3A inducers is not recommended [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Therefore, concomitant use with strong CYP3A inducers is not recommended [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Therefore, concomitant use with strong CYP3A inducers is not recommended [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Therefore, concomitant use with strong CYP3A inducers is not recommended [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Therefore, concomitant use with strong CYP3A inducers is not recommended [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Therefore, concomitant use with strong CYP3A inducers is not recommended [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Avoid food or drink containing grapefruit. (bula de Elexacaftor + tezacaftor + ivacaftor, Interações medicamentosas)

Patients with elevated vitamin A levels may be at increased risk. (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Patients with elevated vitamin A levels may be at increased risk. (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Concomitant Use with CYP3A Inhibitors Exposure to elexacaftor, tezacaftor and ivacaftor are increased when used concomitantly with strong or moderate CYP3A inhibitors. (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Concomitant use of TRIKAFTA may increase exposures of medicinal products that are substrates of these transporters, such as statins, glyburide, nateglinide and repaglinide. (bula de Elexacaftor + tezacaftor + ivacaftor, Interações medicamentosas)

Concomitant Use with CYP3A Inhibitors Exposure to elexacaftor, tezacaftor and ivacaftor are increased when used concomitantly with strong or moderate CYP3A inhibitors. (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Concomitant use of TRIKAFTA may increase exposures of medicinal products that are substrates of these transporters, such as statins, glyburide, nateglinide and repaglinide. (bula de Elexacaftor + tezacaftor + ivacaftor, Interações medicamentosas)

Although other risk factors were present in some cases (such as corticosteroid use, exposure to radiation), a possible risk attributable to treatment with ivacaftor cannot be excluded. (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Although other risk factors were present in some cases (such as corticosteroid use, exposure to radiation), a possible risk attributable to treatment with ivacaftor cannot be excluded. (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Although other risk factors were present in some cases (such as corticosteroid use, exposure to radiation), a possible risk attributable to treatment with ivacaftor cannot be excluded. (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Patients with elevated vitamin A levels may be at increased risk. (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Although other risk factors were present in some cases (such as corticosteroid use, exposure to radiation), a possible risk attributable to treatment with ivacaftor cannot be excluded. (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Although other risk factors were present in some cases (such as corticosteroid use, exposure to radiation), a possible risk attributable to treatment with ivacaftor cannot be excluded. (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Effect of TRIKAFTA on Other Drugs CYP2C9 Substrates Ivacaftor may inhibit CYP2C9; therefore, monitoring of the international normalized ratio (INR) during concomitant use of TRIKAFTA with warfarin is recommended. (bula de Elexacaftor + tezacaftor + ivacaftor, Interações medicamentosas)

Effect of TRIKAFTA on Other Drugs CYP2C9 Substrates Ivacaftor may inhibit CYP2C9; therefore, monitoring of the international normalized ratio (INR) during concomitant use of TRIKAFTA with warfarin is recommended. (bula de Elexacaftor + tezacaftor + ivacaftor, Interações medicamentosas)

When used concomitantly with itraconazole and ketoconazole, ivacaftor AUC increased by 15.6-fold and 8.5-fold, respectively [see Clinical Pharmacology (12.3) ] . (bula de Elexacaftor + tezacaftor + ivacaftor, Interações medicamentosas)

Although other risk factors were present in some cases (such as corticosteroid use, exposure to radiation), a possible risk attributable to treatment with ivacaftor cannot be excluded. (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

When used concomitantly with digoxin or other substrates of P-gp with a narrow therapeutic index such as cyclosporine, everolimus, sirolimus and tacrolimus, caution and appropriate monitoring should be used [see Clinical Pharmacology (12.3) ] . (bula de Elexacaftor + tezacaftor + ivacaftor, Interações medicamentosas)

Concomitant Use with CYP3A Inhibitors Exposure to elexacaftor, tezacaftor and ivacaftor are increased when used concomitantly with strong or moderate CYP3A inhibitors. (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Concomitant Use with CYP3A Inhibitors Exposure to elexacaftor, tezacaftor and ivacaftor are increased when used concomitantly with strong or moderate CYP3A inhibitors. (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Although other risk factors were present in some cases (such as corticosteroid use, exposure to radiation), a possible risk attributable to treatment with ivacaftor cannot be excluded. (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Concomitant Use with CYP3A Inhibitors Exposure to elexacaftor, tezacaftor and ivacaftor are increased when used concomitantly with strong or moderate CYP3A inhibitors. (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Concomitant Use with CYP3A Inhibitors Exposure to elexacaftor, tezacaftor and ivacaftor are increased when used concomitantly with strong or moderate CYP3A inhibitors. (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Although other risk factors were present in some cases (such as corticosteroid use, exposure to radiation), a possible risk attributable to treatment with ivacaftor cannot be excluded. (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

For patients with CF taking hormonal contraceptives who develop rash, consider interrupting TRIKAFTA and hormonal contraceptives. (bula de Elexacaftor + tezacaftor + ivacaftor, Interações medicamentosas)

Although other risk factors were present in some cases (such as corticosteroid use, exposure to radiation), a possible risk attributable to treatment with ivacaftor cannot be excluded. (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

For patients with CF taking hormonal contraceptives who develop rash, consider interrupting TRIKAFTA and hormonal contraceptives. (bula de Elexacaftor + tezacaftor + ivacaftor, Interações medicamentosas)

Transporters Concomitant use of ivacaftor or tezacaftor/ivacaftor with digoxin, a sensitive P-gp substrate, increased digoxin AUC by 1.3-fold, consistent with weak inhibition of P-gp by ivacaftor. (bula de Elexacaftor + tezacaftor + ivacaftor, Interações medicamentosas)

Concomitant Use with CYP3A Inhibitors Exposure to elexacaftor, tezacaftor and ivacaftor are increased when used concomitantly with strong or moderate CYP3A inhibitors. (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Effect of TRIKAFTA on Other Drugs CYP2C9 Substrates Ivacaftor may inhibit CYP2C9; therefore, monitoring of the international normalized ratio (INR) during concomitant use of TRIKAFTA with warfarin is recommended. (bula de Elexacaftor + tezacaftor + ivacaftor, Interações medicamentosas)

Concomitant Use with CYP3A Inhibitors Exposure to elexacaftor, tezacaftor and ivacaftor are increased when used concomitantly with strong or moderate CYP3A inhibitors. (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

For patients with CF taking hormonal contraceptives who develop rash, consider interrupting TRIKAFTA and hormonal contraceptives. (bula de Elexacaftor + tezacaftor + ivacaftor, Interações medicamentosas)

Concomitant Use with CYP3A Inhibitors Exposure to elexacaftor, tezacaftor and ivacaftor are increased when used concomitantly with strong or moderate CYP3A inhibitors. (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Concomitant Use with CYP3A Inhibitors Exposure to elexacaftor, tezacaftor and ivacaftor are increased when used concomitantly with strong or moderate CYP3A inhibitors. (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

John's wort ( Hypericum perforatum ) Strong or Moderate CYP3A Inhibitors The dosage of TRIKAFTA should be reduced when used concomitantly with strong CYP3A inhibitors [see Dosage and Administration (2.4) and Warnings and Precautions (5.6) ] . (bula de Elexacaftor + tezacaftor + ivacaftor, Interações medicamentosas)

For patients with CF taking hormonal contraceptives who develop rash, consider interrupting TRIKAFTA and hormonal contraceptives. (bula de Elexacaftor + tezacaftor + ivacaftor, Interações medicamentosas)

For patients with CF taking hormonal contraceptives who develop rash, consider interrupting TRIKAFTA and hormonal contraceptives. (bula de Elexacaftor + tezacaftor + ivacaftor, Interações medicamentosas)

For patients with CF taking hormonal contraceptives who develop rash, consider interrupting TRIKAFTA and hormonal contraceptives. (bula de Elexacaftor + tezacaftor + ivacaftor, Interações medicamentosas)

For patients with CF taking hormonal contraceptives who develop rash, consider interrupting TRIKAFTA and hormonal contraceptives. (bula de Elexacaftor + tezacaftor + ivacaftor, Interações medicamentosas)

For patients with CF taking hormonal contraceptives who develop rash, consider interrupting TRIKAFTA and hormonal contraceptives. (bula de Elexacaftor + tezacaftor + ivacaftor, Interações medicamentosas)

For patients with CF taking hormonal contraceptives who develop rash, consider interrupting TRIKAFTA and hormonal contraceptives. (bula de Elexacaftor + tezacaftor + ivacaftor, Interações medicamentosas)

For patients with CF taking hormonal contraceptives who develop rash, consider interrupting TRIKAFTA and hormonal contraceptives. (bula de Elexacaftor + tezacaftor + ivacaftor, Interações medicamentosas)

When used concomitantly with digoxin or other substrates of P-gp with a narrow therapeutic index such as cyclosporine, everolimus, sirolimus and tacrolimus, caution and appropriate monitoring should be used [see Clinical Pharmacology (12.3) ] . (bula de Elexacaftor + tezacaftor + ivacaftor, Interações medicamentosas)

Concomitant use of TRIKAFTA may increase exposures of medicinal products that are substrates of these transporters, such as statins, glyburide, nateglinide and repaglinide. (bula de Elexacaftor + tezacaftor + ivacaftor, Interações medicamentosas)

Concomitant use of fluconazole increased ivacaftor AUC by 2.9-fold [see Clinical Pharmacology (12.3) ] . (bula de Elexacaftor + tezacaftor + ivacaftor, Interações medicamentosas)

Although other risk factors were present in some cases (such as corticosteroid use, exposure to radiation), a possible risk attributable to treatment with ivacaftor cannot be excluded. (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Although other risk factors were present in some cases (such as corticosteroid use, exposure to radiation), a possible risk attributable to treatment with ivacaftor cannot be excluded. (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Although other risk factors were present in some cases (such as corticosteroid use, exposure to radiation), a possible risk attributable to treatment with ivacaftor cannot be excluded. (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Effect of TRIKAFTA on Other Drugs CYP2C9 Substrates Ivacaftor may inhibit CYP2C9; therefore, monitoring of the international normalized ratio (INR) during concomitant use of TRIKAFTA with warfarin is recommended. (bula de Elexacaftor + tezacaftor + ivacaftor, Interações medicamentosas)

Although other risk factors were present in some cases (such as corticosteroid use, exposure to radiation), a possible risk attributable to treatment with ivacaftor cannot be excluded. (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Although other risk factors were present in some cases (such as corticosteroid use, exposure to radiation), a possible risk attributable to treatment with ivacaftor cannot be excluded. (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Effect of TRIKAFTA on Other Drugs CYP2C9 Substrates Ivacaftor may inhibit CYP2C9; therefore, monitoring of the international normalized ratio (INR) during concomitant use of TRIKAFTA with warfarin is recommended. (bula de Elexacaftor + tezacaftor + ivacaftor, Interações medicamentosas)

Concomitant Use with CYP3A Inhibitors Exposure to elexacaftor, tezacaftor and ivacaftor are increased when used concomitantly with strong or moderate CYP3A inhibitors. (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Concomitant Use with CYP3A Inhibitors Exposure to elexacaftor, tezacaftor and ivacaftor are increased when used concomitantly with strong or moderate CYP3A inhibitors. (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

For patients with CF taking hormonal contraceptives who develop rash, consider interrupting TRIKAFTA and hormonal contraceptives. (bula de Elexacaftor + tezacaftor + ivacaftor, Interações medicamentosas)

Concomitant use of TRIKAFTA may increase exposures of medicinal products that are substrates of these transporters, such as statins, glyburide, nateglinide and repaglinide. (bula de Elexacaftor + tezacaftor + ivacaftor, Interações medicamentosas)

Concomitant use of TRIKAFTA may increase exposures of medicinal products that are substrates of these transporters, such as statins, glyburide, nateglinide and repaglinide. (bula de Elexacaftor + tezacaftor + ivacaftor, Interações medicamentosas)

Other medicinal products for which exposure may be increased by TRIKAFTA include glimepiride and glipizide; these medicinal products should be used with caution [see Clinical Pharmacology (12.3) ] . (bula de Elexacaftor + tezacaftor + ivacaftor, Interações medicamentosas)

Other medicinal products for which exposure may be increased by TRIKAFTA include glimepiride and glipizide; these medicinal products should be used with caution [see Clinical Pharmacology (12.3) ] . (bula de Elexacaftor + tezacaftor + ivacaftor, Interações medicamentosas)

Other medicinal products for which exposure may be increased by TRIKAFTA include glimepiride and glipizide; these medicinal products should be used with caution [see Clinical Pharmacology (12.3) ] . (bula de Elexacaftor + tezacaftor + ivacaftor, Interações medicamentosas)

Although other risk factors were present in some cases (such as corticosteroid use, exposure to radiation), a possible risk attributable to treatment with ivacaftor cannot be excluded. (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Although other risk factors were present in some cases (such as corticosteroid use, exposure to radiation), a possible risk attributable to treatment with ivacaftor cannot be excluded. (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Concomitant Use with CYP3A Inhibitors Exposure to elexacaftor, tezacaftor and ivacaftor are increased when used concomitantly with strong or moderate CYP3A inhibitors. (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Concomitant Use with CYP3A Inhibitors Exposure to elexacaftor, tezacaftor and ivacaftor are increased when used concomitantly with strong or moderate CYP3A inhibitors. (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Patients with elevated vitamin A levels may be at increased risk. (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Concomitant Use with CYP3A Inhibitors Exposure to elexacaftor, tezacaftor and ivacaftor are increased when used concomitantly with strong or moderate CYP3A inhibitors. (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Concomitant Use with CYP3A Inhibitors Exposure to elexacaftor, tezacaftor and ivacaftor are increased when used concomitantly with strong or moderate CYP3A inhibitors. (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

For patients with CF taking hormonal contraceptives who develop rash, consider interrupting TRIKAFTA and hormonal contraceptives. (bula de Elexacaftor + tezacaftor + ivacaftor, Interações medicamentosas)

For patients with CF taking hormonal contraceptives who develop rash, consider interrupting TRIKAFTA and hormonal contraceptives. (bula de Elexacaftor + tezacaftor + ivacaftor, Interações medicamentosas)

Concomitant use of TRIKAFTA may increase exposures of medicinal products that are substrates of these transporters, such as statins, glyburide, nateglinide and repaglinide. (bula de Elexacaftor + tezacaftor + ivacaftor, Interações medicamentosas)

For patients with CF taking hormonal contraceptives who develop rash, consider interrupting TRIKAFTA and hormonal contraceptives. (bula de Elexacaftor + tezacaftor + ivacaftor, Interações medicamentosas)

For patients with CF taking hormonal contraceptives who develop rash, consider interrupting TRIKAFTA and hormonal contraceptives. (bula de Elexacaftor + tezacaftor + ivacaftor, Interações medicamentosas)

Although other risk factors were present in some cases (such as corticosteroid use, exposure to radiation), a possible risk attributable to treatment with ivacaftor cannot be excluded. (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Effect of TRIKAFTA on Other Drugs CYP2C9 Substrates Ivacaftor may inhibit CYP2C9; therefore, monitoring of the international normalized ratio (INR) during concomitant use of TRIKAFTA with warfarin is recommended. (bula de Elexacaftor + tezacaftor + ivacaftor, Interações medicamentosas)

Effect of TRIKAFTA on Other Drugs CYP2C9 Substrates Ivacaftor may inhibit CYP2C9; therefore, monitoring of the international normalized ratio (INR) during concomitant use of TRIKAFTA with warfarin is recommended. (bula de Elexacaftor + tezacaftor + ivacaftor, Interações medicamentosas)

Concomitant Use with CYP3A Inhibitors Exposure to elexacaftor, tezacaftor and ivacaftor are increased when used concomitantly with strong or moderate CYP3A inhibitors. (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Concomitant Use with CYP3A Inhibitors Exposure to elexacaftor, tezacaftor and ivacaftor are increased when used concomitantly with strong or moderate CYP3A inhibitors. (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Although other risk factors were present in some cases (such as corticosteroid use, exposure to radiation), a possible risk attributable to treatment with ivacaftor cannot be excluded. (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Concomitant use of TRIKAFTA may increase exposures of medicinal products that are substrates of these transporters, such as statins, glyburide, nateglinide and repaglinide. (bula de Elexacaftor + tezacaftor + ivacaftor, Interações medicamentosas)

Concomitant Use with CYP3A Inhibitors Exposure to elexacaftor, tezacaftor and ivacaftor are increased when used concomitantly with strong or moderate CYP3A inhibitors. (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Effect of TRIKAFTA on Other Drugs CYP2C9 Substrates Ivacaftor may inhibit CYP2C9; therefore, monitoring of the international normalized ratio (INR) during concomitant use of TRIKAFTA with warfarin is recommended. (bula de Elexacaftor + tezacaftor + ivacaftor, Interações medicamentosas)

For patients with CF taking hormonal contraceptives who develop rash, consider interrupting TRIKAFTA and hormonal contraceptives. (bula de Elexacaftor + tezacaftor + ivacaftor, Interações medicamentosas)

For patients with CF taking hormonal contraceptives who develop rash, consider interrupting TRIKAFTA and hormonal contraceptives. (bula de Elexacaftor + tezacaftor + ivacaftor, Interações medicamentosas)

For patients with CF taking hormonal contraceptives who develop rash, consider interrupting TRIKAFTA and hormonal contraceptives. (bula de Elexacaftor + tezacaftor + ivacaftor, Interações medicamentosas)

For patients with CF taking hormonal contraceptives who develop rash, consider interrupting TRIKAFTA and hormonal contraceptives. (bula de Elexacaftor + tezacaftor + ivacaftor, Interações medicamentosas)

For patients with CF taking hormonal contraceptives who develop rash, consider interrupting TRIKAFTA and hormonal contraceptives. (bula de Elexacaftor + tezacaftor + ivacaftor, Interações medicamentosas)

Although other risk factors were present in some cases (such as corticosteroid use, exposure to radiation), a possible risk attributable to treatment with ivacaftor cannot be excluded. (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Concomitant Use with CYP3A Inhibitors Exposure to elexacaftor, tezacaftor and ivacaftor are increased when used concomitantly with strong or moderate CYP3A inhibitors. (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Concomitant Use with CYP3A Inhibitors Exposure to elexacaftor, tezacaftor and ivacaftor are increased when used concomitantly with strong or moderate CYP3A inhibitors. (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Other medicinal products for which exposure may be increased by TRIKAFTA include glimepiride and glipizide; these medicinal products should be used with caution [see Clinical Pharmacology (12.3) ] . (bula de Elexacaftor + tezacaftor + ivacaftor, Interações medicamentosas)

Concomitant use of TRIKAFTA may increase exposures of medicinal products that are substrates of these transporters, such as statins, glyburide, nateglinide and repaglinide. (bula de Elexacaftor + tezacaftor + ivacaftor, Interações medicamentosas)

Concomitant Use with CYP3A Inhibitors Exposure to elexacaftor, tezacaftor and ivacaftor are increased when used concomitantly with strong or moderate CYP3A inhibitors. (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Concomitant use of TRIKAFTA may increase exposures of medicinal products that are substrates of these transporters, such as statins, glyburide, nateglinide and repaglinide. (bula de Elexacaftor + tezacaftor + ivacaftor, Interações medicamentosas)

Although other risk factors were present in some cases (such as corticosteroid use, exposure to radiation), a possible risk attributable to treatment with ivacaftor cannot be excluded. (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Although other risk factors were present in some cases (such as corticosteroid use, exposure to radiation), a possible risk attributable to treatment with ivacaftor cannot be excluded. (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

For patients with CF taking hormonal contraceptives who develop rash, consider interrupting TRIKAFTA and hormonal contraceptives. (bula de Elexacaftor + tezacaftor + ivacaftor, Interações medicamentosas)

Concomitant Use with CYP3A Inhibitors Exposure to elexacaftor, tezacaftor and ivacaftor are increased when used concomitantly with strong or moderate CYP3A inhibitors. (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Concomitant use of TRIKAFTA may increase exposures of medicinal products that are substrates of these transporters, such as statins, glyburide, nateglinide and repaglinide. (bula de Elexacaftor + tezacaftor + ivacaftor, Interações medicamentosas)

Concomitant use of TRIKAFTA may increase exposures of medicinal products that are substrates of these transporters, such as statins, glyburide, nateglinide and repaglinide. (bula de Elexacaftor + tezacaftor + ivacaftor, Interações medicamentosas)

Concomitant use of TRIKAFTA may increase exposures of medicinal products that are substrates of these transporters, such as statins, glyburide, nateglinide and repaglinide. (bula de Elexacaftor + tezacaftor + ivacaftor, Interações medicamentosas)

When used concomitantly with digoxin or other substrates of P-gp with a narrow therapeutic index such as cyclosporine, everolimus, sirolimus and tacrolimus, caution and appropriate monitoring should be used [see Clinical Pharmacology (12.3) ] . (bula de Elexacaftor + tezacaftor + ivacaftor, Interações medicamentosas)

Effect of TRIKAFTA on Other Drugs CYP2C9 Substrates Ivacaftor may inhibit CYP2C9; therefore, monitoring of the international normalized ratio (INR) during concomitant use of TRIKAFTA with warfarin is recommended. (bula de Elexacaftor + tezacaftor + ivacaftor, Interações medicamentosas)

Effect of TRIKAFTA on Other Drugs CYP2C9 Substrates Ivacaftor may inhibit CYP2C9; therefore, monitoring of the international normalized ratio (INR) during concomitant use of TRIKAFTA with warfarin is recommended. (bula de Elexacaftor + tezacaftor + ivacaftor, Interações medicamentosas)

Concomitant Use with CYP3A Inhibitors Exposure to elexacaftor, tezacaftor and ivacaftor are increased when used concomitantly with strong or moderate CYP3A inhibitors. (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

When used concomitantly with digoxin or other substrates of P-gp with a narrow therapeutic index such as cyclosporine, everolimus, sirolimus and tacrolimus, caution and appropriate monitoring should be used [see Clinical Pharmacology (12.3) ] . (bula de Elexacaftor + tezacaftor + ivacaftor, Interações medicamentosas)

Concomitant Use with CYP3A Inhibitors Exposure to elexacaftor, tezacaftor and ivacaftor are increased when used concomitantly with strong or moderate CYP3A inhibitors. (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Patients with elevated vitamin A levels may be at increased risk. (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Although other risk factors were present in some cases (such as corticosteroid use, exposure to radiation), a possible risk attributable to treatment with ivacaftor cannot be excluded. (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Effect of TRIKAFTA on Other Drugs CYP2C9 Substrates Ivacaftor may inhibit CYP2C9; therefore, monitoring of the international normalized ratio (INR) during concomitant use of TRIKAFTA with warfarin is recommended. (bula de Elexacaftor + tezacaftor + ivacaftor, Interações medicamentosas)

Effect of TRIKAFTA on Other Drugs CYP2C9 Substrates Ivacaftor may inhibit CYP2C9; therefore, monitoring of the international normalized ratio (INR) during concomitant use of TRIKAFTA with warfarin is recommended. (bula de Elexacaftor + tezacaftor + ivacaftor, Interações medicamentosas)

Concomitant Use with CYP3A Inhibitors Exposure to elexacaftor, tezacaftor and ivacaftor are increased when used concomitantly with strong or moderate CYP3A inhibitors. (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Concomitant Use with CYP3A Inhibitors Exposure to elexacaftor, tezacaftor and ivacaftor are increased when used concomitantly with strong or moderate CYP3A inhibitors. (bula de Elexacaftor + tezacaftor + ivacaftor, Advertências e precauções)

Effect of TRIKAFTA on Other Drugs CYP2C9 Substrates Ivacaftor may inhibit CYP2C9; therefore, monitoring of the international normalized ratio (INR) during concomitant use of TRIKAFTA with warfarin is recommended. (bula de Elexacaftor + tezacaftor + ivacaftor, Interações medicamentosas)

Examples of strong CYP3A inducers include: rifampin, rifabutin, phenobarbital, carbamazepine, phenytoin and St. (bula de Elexacaftor + tezacaftor + ivacaftor, Interações medicamentosas)

Drugs with No Clinically Significant Interactions with TRIKAFTA Ciprofloxacin Ciprofloxacin had no clinically relevant effect on the exposure of tezacaftor or ivacaftor and is not expected to affect the exposure of elexacaftor. (bula de Elexacaftor + tezacaftor + ivacaftor, Interações medicamentosas)